Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Regn crawled time : 06:00 save search
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.14%
H: 0.32%
C: -0.57%
dupixent first japan urticaria world
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.66%
H: 0.0%
C: -1.59%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.14%
H: 0.32%
C: -0.57%
dupixent first japan urticaria world
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review
Published: 2023-09-26 (Crawled : 06:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.39%
H: 0.23%
C: 0.23%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.33%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.04%
H: 0.65%
C: -0.31%
dupixent fda children review treatment
Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
Published: 2022-10-11 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.33%
H: 2.65%
C: 1.22%
dupixent children week
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old
Published: 2022-10-11 (Crawled : 06:00) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.33%
H: 2.65%
C: 1.22%
dupixent children week
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | $92.9 -2.18% 880
|
Health Technology
| Email alert
Add to watchlist
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
| Email alert
Add to watchlist
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
Published: 2022-06-02 (Crawled : 06:00) - globenewswire.com
XOMA | $24.74 -4.29% -4.49% 6.1K
|
Health Technology
|
| O: -8.73%
H: 5.95%
C: 4.37%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -2.18%
H: 0.0%
C: -3.71%
acquisition payment milestone
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis
Published: 2022-05-31 (Crawled : 06:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.5%
H: 0.54%
C: 0.54%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -4.05%
dupixent fda review
Press Release: FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis
Published: 2022-05-31 (Crawled : 06:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -2.5%
H: 0.54%
C: 0.54%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -3.21%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -4.05%
dupixent fda review
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation
Published: 2022-04-07 (Crawled : 06:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis
Published: 2022-04-04 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitis
Published: 2022-04-04 (Crawled : 06:00) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.76%
H: 0.0%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.74%
H: 0.6%
C: -0.23%
dupixent fda review order
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
Published: 2021-09-21 (Crawled : 06:00) - globenewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.32%
H: 0.56%
C: 0.0%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.26%
H: 1.82%
C: 0.29%
dermatitis atopic dermatitis dupixent
Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients
Published: 2021-07-29 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.69%
H: 0.08%
C: -0.33%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.38%
H: 0.52%
C: -0.93%
hiv urticaria dupixent
Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19
Published: 2021-07-20 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.29%
H: 1.02%
C: 0.78%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.52%
H: 0.92%
C: -0.18%
covid treatment antibody casirivimab
Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression
Published: 2021-06-25 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.55%
H: 0.68%
C: 0.57%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: -0.16%
H: 1.64%
C: 1.28%
treatment lung cancer europe cancer
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.